Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMYTNASDAQ:GRINASDAQ:INDVNASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMYTAmryt Pharma$14.70+0.1%$14.64$6.41▼$14.77$940.21M0.84757,360 shs2.39 million shsGRIGRI Bio$1.82+9.0%$4.54$1.10▼$106.04$877K-1.72281,127 shs241,291 shsINDVIndivior$11.56+7.4%$9.48$7.33▼$18.59$1.59B0.93970,409 shs1.46 million shsSLSSELLAS Life Sciences Group$1.40+4.5%$1.18$0.77▼$1.84$127.19M2.531.37 million shs2.44 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMYTAmryt Pharma0.00%0.00%0.00%0.00%0.00%GRIGRI Bio0.00%+20.53%-68.99%-82.59%-98.12%INDVIndivior0.00%+28.30%+17.96%-3.59%-38.54%SLSSELLAS Life Sciences Group0.00%+7.69%+20.69%+38.61%-9.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMYTAmryt PharmaN/AN/AN/AN/AN/AN/AN/AN/AGRIGRI Bio2.3303 of 5 stars3.52.00.00.03.30.01.3INDVIndivior3.4963 of 5 stars3.63.00.00.03.41.71.9SLSSELLAS Life Sciences Group0.7506 of 5 stars0.04.00.00.02.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMYTAmryt Pharma 0.00N/AN/AN/AGRIGRI Bio 3.00Buy$115.506,246.15% UpsideINDVIndivior 3.25Buy$15.0029.76% UpsideSLSSELLAS Life Sciences Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AMYT, GRI, INDV, and SLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/6/2025INDVIndiviorPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $13.001/28/2025INDVIndiviorRODMAN&RENSHAWSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy1/28/2025INDVIndiviorRodman & RenshawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMYTAmryt Pharma$222.54M4.22$0.98 per share14.98$5.58 per share2.63GRIGRI BioN/AN/AN/AN/A$5.22 per shareN/AINDVIndivior$1.17B1.36$2.34 per share4.94N/A∞SLSSELLAS Life Sciences Group$1M127.19N/AN/A($0.25) per share-5.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMYTAmryt Pharma$1M-$0.06N/A735.00N/A-8.19%1.70%0.75%N/AGRIGRI Bio-$13.04M-$11.56N/AN/AN/AN/A-289.05%-165.01%5/9/2025 (Estimated)INDVIndivior$2M-$0.31N/A6.76N/A-3.96%-241.73%15.09%N/ASLSSELLAS Life Sciences Group-$37.34M-$0.52N/AN/AN/AN/A-629.46%-178.65%5/13/2025 (Estimated)Latest AMYT, GRI, INDV, and SLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067N/AN/AN/AN/AN/A5/9/2025N/AGRIGRI Bio-$4.08N/AN/AN/AN/AN/A4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 million3/20/2025Q4 2024SLSSELLAS Life Sciences Group-$0.1067-$0.08+$0.0267-$0.08N/AN/A2/20/2025Q4 2024INDVIndivior$0.32$0.32N/A$0.07$262.35 million$298.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMYTAmryt PharmaN/AN/AN/AN/AN/AGRIGRI Bio$1.91104.95%N/AN/A N/AINDVIndiviorN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMYTAmryt Pharma0.641.570.94GRIGRI BioN/A3.103.10INDVIndiviorN/A0.830.65SLSSELLAS Life Sciences GroupN/A2.262.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMYTAmryt Pharma71.31%GRIGRI Bio33.95%INDVIndivior60.33%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipAMYTAmryt Pharma5.66%GRIGRI Bio0.13%INDVIndiviorN/ASLSSELLAS Life Sciences Group1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMYTAmryt Pharma2,02063.96 million60.34 millionNot OptionableGRIGRI Bio1525,0008.92 millionNot OptionableINDVIndivior1,164137.88 millionN/ANot OptionableSLSSELLAS Life Sciences Group1090.85 million69.54 millionNot OptionableAMYT, GRI, INDV, and SLS HeadlinesRecent News About These CompaniesWhy SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 8.95%April 26 at 9:58 AM | aaii.comSELLAS Life Sciences Group (NASDAQ:SLS) Trading 1.6% Higher - Time to Buy?April 26 at 2:34 AM | marketbeat.comSELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual MeetingApril 23, 2025 | quiverquant.comSELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2025 | globenewswire.comSellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trialApril 9, 2025 | markets.businessinsider.comSELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AMLApril 8, 2025 | globenewswire.comSELLAS Life Sciences Group, Inc. Common Stock (SLS) Insider ActivityMarch 30, 2025 | nasdaq.comSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 21, 2025 | finanznachrichten.deSELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 20, 2025 | globenewswire.comSellas reports Phase IIa trial data of SLS009 for DLBCL treatmentFebruary 21, 2025 | msn.comSELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCLFebruary 20, 2025 | finanznachrichten.deSELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trialFebruary 20, 2025 | msn.comSellas Life Sciences’ zanubrutinib combination shows efficacy in DLBCLFebruary 20, 2025 | markets.businessinsider.comSELLAS Life Sciences Reports Promising Phase 2a Data for SLS009 in Combination with Zanubrutinib in DLBCL PatientsFebruary 20, 2025 | quiverquant.comSELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCLFebruary 20, 2025 | globenewswire.comSellas Life Sciences Group Inc (SLS) Stock: Understanding Its Underlying ValueFebruary 3, 2025 | bovnews.comWhy SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 21.80%February 1, 2025 | aaii.comSellas Life Sciences Group Inc (SLS) Stock Dilemma: A Surge That Has Everyone Talking—What’s the Real Story?January 30, 2025 | bovnews.comSellas $25M registered direct offering priced at $1.27 per share and warrantJanuary 29, 2025 | markets.businessinsider.comWhy SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Down 17.02%January 29, 2025 | aaii.comSELLAS secures $25 million in registered direct offeringJanuary 28, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound PotentialWhy Analysts See Double-Digit Upside in CAVA StockBy Gabriel Osorio-Mazilli | April 6, 2025View Why Analysts See Double-Digit Upside in CAVA StockAmazon's Earnings Could Fuel a Rapid Breakout By Sam Quirke | April 23, 2025View Amazon's Earnings Could Fuel a Rapid Breakout AMYT, GRI, INDV, and SLS Company DescriptionsAmryt Pharma NASDAQ:AMYTAmryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.GRI Bio NASDAQ:GRI$1.82 +0.15 (+8.98%) As of 04/25/2025 04:00 PM EasternGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Indivior NASDAQ:INDV$11.56 +0.80 (+7.43%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$11.69 +0.13 (+1.12%) As of 04/25/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.SELLAS Life Sciences Group NASDAQ:SLS$1.40 +0.06 (+4.48%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.42 +0.02 (+1.07%) As of 04/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
